The management of agitated, combative, fearful critically ill patients is a significant challenge for critical care nurses. Intravenously administered haloperidol can be effective in treating these patients. Because the U.S. Food and Drug Administration has not approved the use of haloperidol intravenously, there are no widely accepted guidelines for intravenous use of this drug. This chapter reviews the literature and provides information to critical care nurses in the use of intravenous haloperidol. Haloperidol’s pharmacologic properties are described; several published case studies are reviewed; and potential adverse effects associated with haloperidol’s use are presented
Analgesia and Sedation in the Critically Ill Patient| November 01 1991
Intravenous Haloperidol for Tranquilization in Critical Care Patients: A Review and Critique
Scott R. Ziehm, RN, ND
From the School of Nursing/Department of Nursing, University of California, San Francisco, San Francisco, California.
Reprint requests to Scott R. Ziehm, RN, ND, School of Nursing, University of California, San Francisco, San Francisco, CA 94143-0604.
Search for other works by this author on:
AACN Adv Crit Care (1991) 2 (4): 765–777.
- Views Icon Views
- Share Icon Share
- Tools Icon Tools
- Search Site
Scott R. Ziehm; Intravenous Haloperidol for Tranquilization in Critical Care Patients: A Review and Critique. AACN Adv Crit Care 1 November 1991; 2 (4): 765–777. doi: https://doi.org/10.4037/15597768-1991-4016
Download citation file: